Edwards Lifesciences

Edwards Lifesciences demonstrates excellent capital allocation, averaging 22.2% return on capital while reducing shares outstanding through buybacks. Management deploys capital at rates well above the cost of capital, creating significant value for shareholders.

The allocation between reinvestment, buybacks, and dividends appears disciplined and shareholder-friendly.